Serum concentrations after switching from originator infliximab to the biosimilar CT-P13 in patients with quiescent inflammatory bowel disease (SECURE): an open-label, multicentre, phase 4 non-inferiority trial-Reference-Cited by-同舟云学术

Serum concentrations after switching from originator infliximab to the biosimilar CT-P13 in patients with quiescent inflammatory bowel disease (SECURE): an open-label, multicentre, phase 4 non-inferiority trial

Published:2018-06 Issue:6 Volume:3 Page:404-412
ISSN:2468-1253
Container-title:The Lancet Gastroenterology & Hepatology
language:en
Short-container-title:The Lancet Gastroenterology & Hepatology

Author:

Strik Anne S,van de Vrie Wim,Bloemsaat-Minekus Joanne P J,Nurmohamed Michael,Bossuyt Peter J J,Bodelier Alexander,Rispens Theo,van Megen Yvonne J B,D'Haens Geert R

Publisher

Elsevier BV

Subject

Gastroenterology,Hepatology

Reference21 articles.

1. A randomised, double-blind, multicentre, parallel-group, prospective study comparing the pharmacokinetics, safety, and efficacy of CT-P13 and innovator infliximab in patients with ankylosing spondylitis: the PLANETAS study;Park;Ann Rheum Dis,2013

2. A randomised, double-blind, parallel-group study to demonstrate equivalence in efficacy and safety of CT-P13 compared with innovator infliximab when coadministered with methotrexate in patients with active rheumatoid arthritis: the PLANETRA study;Yoo;Ann Rheum Dis,2013

3. ECCO position statement: the use of biosimilar medicines in the treatment of inflammatory bowel disease (IBD);Danese;J Crohns Colitis,2013

4. Switching from originator infliximab to biosimilar CT-P13 compared with maintained treatment with originator infliximab (NOR-SWITCH): a 52-week, randomised, double-blind, non-inferiority trial;Jørgensen;Lancet,2017

5. Clinical experience of the use of CT-P13, a biosimilar to infliximab in patients with inflammatory bowel disease: a case series;Kang;Dig Dis Sci,2015

Cited by 58 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Clinical experience of using biosimilars in Crohn’s disease and their effectiveness;Expert Opinion on Biological Therapy;2024-09-13

2. Evaluating the Efficacy of Infliximab in Inflammatory Bowel Disease: A Systematic Review of the Literature;Cureus;2024-08-01

3. Anti-TNFα in inflammatory bowel disease: from originators to biosimilars;Frontiers in Pharmacology;2024-07-24

4. Systematic review: effectiveness and safety of switching between originator infliximab and biosimilar infliximab in patients with inflammatory bowel disease;Expert Opinion on Biological Therapy;2024-07-02

5. Is infliximab therapy currently relevant in patients with inflammatory bowel diseases? (review);Koloproktologia;2024-06-21